Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) will report first quarter 2026 financial results on May 12, 2026 with a live webcast at 8:00 a.m. ET. Management will review Q1 results and provide a corporate update.
Investors can access the webcast under Events and Presentations on the Arvinas investor website; a replay will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction – ARVN
In the May 5 session, ARVN declined 1.58%, reflecting a mild negative market reaction. Argus tracked a peak move of +19.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Earnings date notice | Neutral | -1.8% | Announced timing and webcast details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last earnings date announcement saw a modest negative move of -1.8% on neutral scheduling news.
Recent news for Arvinas has included a mix of clinical, regulatory, and corporate milestones. An earlier earnings date notice on Feb 17, 2026 led into 4Q/2025 results on Feb 24, with the scheduling headline itself associated with a -1.8% move. Against this backdrop of major catalysts like FDA approval for VEPPANU and positive ARV‑102 data, the new Q1 2026 earnings date continues the cadence of regular investor updates rather than introducing new fundamentals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first-and-only U.S. Food and Drug Administration (FDA) approved PROTAC, a type of heterobifunctional protein degrader, VEPPANU (vepdegestrant), for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle. Arvinas is headquartered in New Haven, Connecticut.For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Alyssa Kuciunas
+1 (331) 481-3751
alyssa.kuciunas-c@arvinas.com
